Overview

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. This study is going to look at what effects rosiglitazone has on prostate specific antigen (PSA) levels.
Phase:
Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Dana-Farber Cancer Institute
Treatments:
Androgens
Rosiglitazone